Lonza said on Thursday it plans to exit the capsules and health ingredients business, as the Swiss contract drugmaker faced a ...
The life-sciences company will focus on its core business, including drug development, with restructuring and a divestment ...
Swiss contract drugmaker Lonza plans to exit its capsules and health ingredients (CHI) business, it said on Thursday, after ...
With a new CEO at the helm, Swiss CDMO Lonza is looking to revivify its business by doubling down on contract manufacturing ...
Find insight on Lonza, regenerative stem cell-based therapies and more in the latest Market Talks covering the health care ...
Lonza Group AG / Key word (s): Strategic Company Decision Lonza Investor Update 2024 Outlines Strategy, New Organizational Structure and Guidance 12-Dec-2024 / 06:25 CET/CEST Release of an ad hoc ...
Swiss healthcare manufacturing organization Lonza saw its shares rise 7% to 559.40 francs in early trading, as it announced ...
Morgan Stanley analyst Thibault Boutherin maintained a Buy rating on Lonza Group Ltd (LONN – Research Report) today and set a price target of CHF600.00. Pick the best stocks and maximize your ...
Investing.com -- Lonza’s shares rose over 6% on Thursday following the company’s announcement of plans to divest its Capsules ...
Lonza forecasts 2025 CER sales growth of nearly 20%, supported by organic growth and acquisitions, with CORE EBITDA margins nearing 30%. The streamlined organizational model, operational by Q2 2025, ...
Jean-Marc Huët to be appointed as Chair to succeed Maarten Das Retirement of Maarten Das as non-executive member and Chair Reappointment of Alexander de Carvalho as non-executive member Amsterdam, 13 ...